REVERSING CATARACT RESTORING SIGHT

A FIRST-IN-CLASS INJECTABLE FOR REVERSING CATARACTS

Our team of scientists is developing a first-in-class small molecule for reversing cataracts, to be delivered via intra-vitreal injection.  TPT-161 is an investigational drug designed to restore normal lens function by unfolding misfolded proteins and breaking down disulfide bonds, both mechanisms associated with cataracts formation and eventual blindness.

A Multi-Targeting Small Molecule NCE Approach to Treating and Reversing Dysfunctional Lens Syndrome

WHAT IS IT?

  • TPT-161 is a small molecule targeting two known mechanisms of lens opacity and hardening: protein misfolding and disulfide bond formation.
  • TPT-161 is a co-drug of an alpha-crystallin chaperone plus a reducing agent.
  • The alpha-crystallin chaperone ligands bind and stabilize alpha-crystallin’s transparent, chaperone-active form to both prevent and reverse protein aggregation of the Beta and Gamma crystallins.
  • In addition to this first mechanism, a reducing agent reduces disulfide bond formations on lens proteins to reverse aggregation.
  • Together, we aim to address a large portion of nuclear sclerotic cataracts and rejuvenate vision for tens of millions of people globally.

WHAT IS THE MECHANISM?

  • Alpha-crystallins are molecular chaperones andthe key target for modulating total cystallin protein aggregation in the lens.
  • With age, alpha-crystallins become unstable
  • Alpha-crystallins are a genetically validated target for presbyopia and cataracts.
  • An alpha-crystallin chaperone ligand binds at the dimer interface stabilizing the dimer and preventing dissociation to an unstable monomer, and with that, reversing aggregation and lens opacity.
  • Reducing Agents reduce disulfide bond formations on lens proteins and restore the reductive capacity of glutathione, the lenses’ natural reducing agent (antioxidant).
  • A reducing agent rejuvenates reduced glutathione, the natural lenses own reducing agent, that maintains lens clarity.

WHAT IS THE INDICATION?

  • Over 2 billion people suffer from presbyopia and several hundred million have cataracts, which, without surgical intervention, leads to complete blindness
  • Both presbyopia and cataracts are conditions on the spectrum of dysfunctional lens syndrome, the natural hardening of the lens from the initial loss of accommodation through to blindness.
  • TPT-161 will rejuvenate the lens of the aging eye.

WHAT IS THE CAUSE?

  • Both cataracts and presbyopia are the result of lens hardening, a natural process which commences early in life and continues until complete blindness along the aging spectrum.
  • Proteins misfold in the lens and create lens aggregation, and oxidative stress creates further opacity.
  • TPT-161 will address the two mechanisms for lens hardening and opacification and rejuvenate the lens to a more youthful state.

© Tenpoint Therapeutics, Ltd. 2024 ALL RIGHTS RESERVED
TENPOINT THERAPEUTICS and BRIMOCHOL are trademarks of Tenpoint Therapeutics, Ltd.

Tenpoint Therapeutics, Ltd.
London Innovation Centre
20 Water Street, 4th Floor
Office 3, Wood Wharf
London, E14 9GG